Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
metyrapone · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Session 1 | EXPERIMENTAL | Subjects will be randomized to receive Dose 1 of Metyrapone 0.04 gram per kilogram (g/kg) and Dose 2 of AEBCD sequence. In AEBCD sequence A is placebo, E Alprazolam, B GSK6561679 10 milligram (mg), C GSK6561679 50 mg and D GSK6561679 400 mg. Wash-out period will be of 7 days. |
| Session 2 | EXPERIMENTAL | Subjects will be randomized to receive Dose 1 of Metyrapone 0.04 g/kg and Dose 2 of BACED sequence. In BACED sequence B is GSK6561679 10 mg, A placebo, C GSK6561679 50 mg, E Alprazolam, and D GSK6561679 400 mg. Wash-out period will be of 7 days. |
| Session 3 | EXPERIMENTAL | Subjects will be randomized to receive Dose 1 of Metyrapone 0.04 g/kg and Dose 2 of CBEAD sequence. In CBEAD sequence C is GSK6561679 50 mg, B GSK6561679 10 mg, E Alprazolam, A placebo, and D GSK6561679 400 mg. Wash-out period will be of 7 days. |
| Session 4 | EXPERIMENTAL | Subjects will be randomized to receive Dose 1 of Metyrapone 0.04 g/kg and Dose 2 of ECABD sequence. In ECABD sequence E is Alprazolam, C is GSK6561679 50 mg, A placebo, B GSK6561679 10 mg and D GSK6561679 400 mg. Wash-out period will be of 7 days. |
| Session 5 | EXPERIMENTAL | Subjects will be randomized to receive Dose 1 of Metyrapone 0.04 g/kg and Dose 2 of GSK561679 400 mg and alprazopam placebo. Wash-out period will be of 7 days. |
| Name | Type | Description |
|---|---|---|
| metyrapone | DRUG | Metyrapone will be available as 250 mg dose capsule. |
| alprazolam | DRUG | Alprazolam capsules will be available with dose strength of 0.25mg |
| placebo | DRUG | GSK561679 placebo tablets visually match the active GSK561679 tablets. Placebo to match Alprazolam is a hard gelatine capsule that visually matches active Alprazolam capsules. |
| GSK561679 | DRUG | GSK561679 tablets will be available with dose strength of 50, 10 and 200 mg. |
Inclusion: * Healthy male subjects * non-smoker * normal ECG Exclusion: * shift workers * vegetarians * persons who travel distances * persons participating in a psychology or psychiatry course
Metyrapone is being investigated for use in depressive disorder and anxiety disorders. It is a small molecule in Phase 1 clinical development. The drug is being studied for its effects on the body's system that controls the balance of many hormones, which may relate to these psychiatric conditions.
Metyrapone is being developed by GSK plc, which trades under the ticker GSK. The company is conducting clinical research on this small molecule for psychiatric indications, specifically depressive disorder and anxiety disorders.
Metyrapone is in Phase 1 clinical development. It is an investigational drug, not yet approved, and is being studied for depressive disorder and anxiety disorders. One Phase 1 trial has been completed, involving 20 participants.
Metyrapone has one completed clinical trial registered as NCT00426608. This Phase 1 study investigated the effects of GSK561679 on the body's hormone-balancing system. The trial enrolled 20 healthy male volunteers in the United Kingdom, with participants aged 18 years and older.
Yes, metyrapone is also known as GSK561679. The clinical trial NCT00426608, which studied metyrapone, is titled 'To Investigate Effects GSK561679 on Part of the Body's System That Controls the Balance of Many of the Hormones.' This alternative name is used in the trial registration.